株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

中国の独立系臨床検査産業レポート

China Independent Clinical Laboratory Industry Report, 2016-2020

発行 ResearchInChina 商品コード 248741
出版日 ページ情報 英文 135 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。
Back to Top
中国の独立系臨床検査産業レポート China Independent Clinical Laboratory Industry Report, 2016-2020
出版日: 2016年09月21日 ページ情報: 英文 135 Pages
概要

当レポートでは、中国の独立系臨床検査産業について調査分析し、産業政策、市場環境、現状、競合情勢、動向と見通し、上流/下流産業の発展などについてまとめ、主要企業プロファイルも含めてお届けいたします。

第1章 独立系医療診断の概要

  • 定義
  • 産業チェーン

第2章 中国の独立系臨床検査産業の概要

  • 政策環境
  • 国際市場
    • 現状
    • 企業分析
  • 開発
  • 競合情勢

第3章 中国の独立系臨床検査産業の上流/下流部門

  • 上流市場
  • 下流市場

第4章 中国の主要企業

  • Kingmed Diagnostics Co., Ltd.
  • ADICON
  • Zhejiang Dian Diagnostics Co., Ltd.
  • Da An Gene Co., Ltd. of Sun Yat-Sen University
  • Nymphavn Biotechnology Corporation Ltd.
  • Surexam Biotechnology Co., Ltd.
  • Ningbo Medicalsystem Biotechnology Co., Ltd.
  • Amoy Diagnostics Co., Ltd.
  • CapitalBio
  • Beijing Adinovo Gene Technology Co., Ltd.
  • Kindstar Global
  • Deyi Diagnostics
  • Beijing IPE Biotechnology Co. Ltd

第5章 予測および見通し

  • 産業の発展
  • 企業間の経営状況比較

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: ZYM080

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory market size has been growing radically in recent years, reaching about RMB6.5 billion with a year-on-year increase of 37.4% in 2015; it is expected to grow rapidly at a rate of 30%-40% over the next three to five years and report RMB29.2 billion in 2020.

There are approximately200 independent clinical laboratory enterprises in China, mainly comprehensive diagnostic chains and special diagnostic enterprises. KingMed Diagnostics, Dian Diagnostics, ADICON Clinical Laboratories, and DaAn Health (invested by Da An Gene), which hold a combined market share of 70% and all adopt chain-based model of comprehensive diagnostic services. By the end of 2015, the four enterprises separately had 31, 26, 20 and 8 independent clinical laboratories. While expanding clinical laboratory services actively, all companies are deploying " laboratory +" industrial chain vigorously.

As a titan in China independent clinical laboratory industry, KingMed Diagnostics earned the revenue of RMB2.5 billion to RMB3 billion in 2015 with 40% market share. In the past two years, KingMed Diagnostics has been involved in production and sale of in vitro diagnostic products through acquisitions and independent R & D; moreover, it has made layout on "laboratory + Internet" services by acquiring GoHeath (Guangzhou Jinzhun), access to Tmall's online pharmacies, etc..

Second to KingMed Diagnostics, Dian Diagnostics gained the revenue of RMB1.079 billion from independent clinical laboratory in 2015. In recent years, the company has implemented the strategy of horizontal expansion, vertical digging, technological innovation and industrial chain integration aggressively. It has arranged the " diagnosis +" ecosystem which refers to the expansion of other related services such as health management, judicial diagnostics, medicine CRO, cold chain logistics and mobile health with a focus on "diagnostic services + products". Since November 2015, the company has acquired Freda,Yuanding, ShengshiKehua, Faith Medical, Kingpe and many other high-quality IVD distributors for over RMB1 billion totally. In 2015, the company launched a new mode for chain expansion of physical examination services -- a health management center (Hangzhou Full-process International Health Medical Management Center Co., Ltd.) established with Hangzhou Jiebai, Baida Group. Meanwhile, Dian Diagnostics signed strategic cooperation agreements with The Johns Hopkins Hospital and AliHealth respectively to explore the "diagnosis + Internet" business mode energetically. At the beginning of 2016, Dian Diagnostics collaborated with Tigermed to set up a joint venture -- Shanghai Teddy Medical Institute Co., Ltd., marking the former's foray into pharmaceutical CRO.

The third-ranked ADICON Clinical Laboratories which still enjoys superiority in East China has not realized the distribution of nationwide chain operation, but its special laboratory items have showed strong competitiveness. The company is not only authorized by the global pharmaceutical giant Roche to become "Roche's Demonstration Laboratory in China", but also cooperates with Siemens Healthineers, Japan SRL, South Korea SCL, France Bio Mérieux, etc. in medical diagnostics.

Being bullish about the prospects of the Chinese independent clinical laboratory market, a number of small and medium Chinese independent clinical laboratory companies have drawn or plan to draw support fromthe capital market to further expand the clinical laboratory market. In 2014-mid-2016, Surexam Biotechnology, Shanghai Labway, Beijing Lepu, Shanghai Biotecan, Jiangsu Superbio, Beijing Lawke and other companies went public at NEW OTCBB in China. Wherein, Jiangsu Superbio witnessed the fastest revenue growth in clinical laboratory, namely the year-on-year surge of 161.0% in 2015; Shanghai Biotecan took the second place with the CAGR of 92.1% in 2013-2015. Shanghai Labway Clinical Laboraory obtained the clinical laboratory revenue of RMB127.8 million in 2015, but the revenue growth has slowed down due to the construction and expansion of laboratories in recent years.

‘China Independent Clinical Laboratory Industry Report, 2016-2020’ highlights the followings:

  • Policy environment, international market, development status, and competitive landscape of China's independent clinical laboratory industry;
  • Upstream and downstream markets of China's independent clinical laboratory industry and their impacts;
  • Operation, and independent clinical laboratory business of 19 relevant enterprises in China;
  • Development outlook of China's independent clinical laboratory industry in 2016-2020 and operational comparison among key players.

Table of Contents

1. Overview of Independent Clinical Laboratory

  • 1.1. Definition
  • 1.2. Industry Chain

2. Overview of China Independent Clinical Laboratory Industry

  • 2.1. Policy Environment
    • 2.1.1. Access Policy
    • 2.1.2. Industry Policy
  • 2.2. International Market
    • 2.2.1. Status Quo
    • 2.2.2. Benchmarking Enterprises
  • 2.3. Development
  • 2.4. Competitive Landscape

3. Upstream and Downstream Markets of China Independent Clinical Laboratory Industry

  • 3.1. Upstream Market
    • 3.1.1. Status Quo
    • 3.1.2. Competition Pattern
  • 3.2. Downstream Market
    • 3.2.1. Independent Clinical Laboratory Market Sees Huge Capacity
    • 3.2.2. Healthcare Reform Boosts the Rapid Development of Independent Clinical Laboratory Market
    • 3.2.3. Demand Diversification Promotes the Upgrading of Independent Clinical Laboratory Industry
    • 3.2.4. Healthcare Demand Growth Propels the Independent Clinical Laboratory Forward Faster
    • 3.2.5. Internet Will Stimulate the Business Model Upgrade of Independent Clinical Laboratory Industry

4. Key Players

  • 4.1. KingMed Diagnostics
    • 4.1.1. Profile
    • 4.1.2. Operation
    • 4.1.3. Revenue Structure
    • 4.1.4. Gross Margin
    • 4.1.5. R&D and Investment
    • 4.1.6. Independent Clinical Laboratory
    • 4.1.7. Client and Supplier
    • 4.1.8. Forecast and Outlook
  • 4.2. ADICON
    • 4.2.1. Profile
    • 4.2.2. Independent Clinical Laboratory
    • 4.2.3. Development
  • 4.3. Dian Diagnostics
    • 4.3.1. Profile
    • 4.3.2. Operation
    • 4.3.3. Revenue Structure
    • 4.3.4. Gross Margin
    • 4.3.5. R&D and Investment
    • 4.3.6. Independent Clinical Laboratory
    • 4.3.7. Client and Supplier
    • 4.3.8. Forecast and Outlook
  • 4.4. DAAN Gene
    • 4.4.1. Profile
    • 4.4.2. Operation
    • 4.4.3. Revenue Structure
    • 4.4.4. Gross Margin
    • 4.4.5. R&D and Investment
    • 4.4.6. Independent Clinical Laboratory
    • 4.4.7. Client and Supplier
    • 4.4.8. Forecast and Outlook
  • 4.5. Shanghai Labway Clinical Laboratory Co., Ltd.
    • 4.5.1. Profile
    • 4.5.2. Operation
    • 4.5.3. Revenue Structure
    • 4.5.4. Gross Margin
    • 4.5.5. R&D and Investment
    • 4.5.6. Independent Clinical Laboratory
    • 4.5.7. Client and Supplier
    • 4.5.8. Forecast and Outlook
  • 4.6. NYMPHAVN Biotechnology
    • 4.6.1. Profile
    • 4.6.2. Operation
    • 4.6.3. Revenue Structure
    • 4.6.4. Gross Margin
    • 4.6.5. R&D and Investment
    • 4.6.6. Independent Clinical Laboratory
    • 4.6.7. Forecast and Outlook
  • 4.7. SurExam Bio-Tech Co., Ltd.
    • 4.7.1. Profile
    • 4.7.2. Operation
    • 4.7.3. Revenue Structure
    • 4.7.4. Gross Margin
    • 4.7.5. R&D and Investment
    • 4.7.6. Independent Clinical Laboratory
    • 4.7.7. Client and Supplier
    • 4.7.8. Forecast and Outlook
  • 4.8. Ningbo Medicalsystem Biotechnology Co., Ltd.
    • 4.8.1. Profile
    • 4.8.2. Operation
    • 4.8.3. Revenue Structure
    • 4.8.4. Gross Margin
    • 4.8.5. R&D and Investment
    • 4.8.6. Independent Clinical Laboratory
    • 4.8.7. Client and Supplier
    • 4.8.8. Forecast and Outlook
  • 4.9. Beijing Lawke Health Laboratory Co., Ltd.
    • 4.9.1. Profile
    • 4.9.2. Operation
    • 4.9.3. Revenue Structure
    • 4.9.4. Gross Margin
    • 4.9.5. Forecast and Outlook
  • 4.10. Beijing Lepu Gene Technology Co.,Ltd.
    • 4.10.1. Profile
    • 4.10.2. Operation
    • 4.10.3. Gross Margin
    • 4.10.4. Forecast and Outlook
  • 4.11. Shanghai Biotecan Pharmaceuticals Co., Ltd.
    • 4.11.1. Profile
    • 4.11.2. Operation
    • 4.11.3. Revenue Structure
    • 4.11.4. Gross Margin
    • 4.11.5. Independent Clinical Laboratory
    • 4.11.6. Forecast and Outlook
  • 4.12. Jiangsu Superbio Life Science Co., Ltd.
    • 4.12.1. Profile
    • 4.12.2. Operation
    • 4.12.3. Revenue Structure
    • 4.12.4. Gross Margin
    • 4.12.5. Client and Supplier
    • 4.12.6. Forecast and Outlook
  • 4.13. Other Enterprises
    • 4.13.1. Kindstar Global
    • 4.13.2. Xiamen Amoy Diagnostics Co., Ltd.
    • 4.13.3. CapitalBio Corporation
    • 4.13.4. Beijing Adinovo Technologies Co., Ltd.
    • 4.13.5. Beijing Deyi Diagnostics Technology Co., Ltd.
    • 4.13.6. IPE Biotechnology Co., Ltd.
    • 4.13.7. Centre Testing International

5. Forecast and Outlook

  • 5.1. Industry Development
  • 5.2. Operation Comparison between Enterprises
    • 5.2.1. Revenue
    • 5.2.2. Gross Margin

Selected Charts:

  • Independent Clinical Laboratory Industry Chain
  • Comparison of Independent Clinical Laboratory Undertakers between China and USA
  • Policies Concerning Independent Clinical Laboratory Industry in China, 2010-2016
  • Market Share of Independent Clinical Laboratories in Major Countries
  • U.S. Independent Clinical Laboratory Market Share by Test Item
  • U.S. Clinical Laboratory Market Share by Demand Side
  • Revenue and Net Income of Quest, 2009-2016
  • Revenue of Quest Diagnostics by Business, 2014-2015
  • Major M&As of Quest Diagnostics, 2006-2015
  • Revenue and Operating Income of LabCorp, 2010-2016
  • Revenue Breakdown of LabCorp by Business, 2013-2016
  • Major M&As of LabCorp, 2007-2015
  • Market Scale of independent clinical laboratory industry in China,2013-2016
  • Revenue CAGR of Some Independent Clinical Laboratory Enterprises in China, 2012-2015
  • Market Share of Major Enterprises in China's Independent Clinical Laboratory Industry, 2015
  • Basic Characteristics and Market Share of Major Independent Clinical Laboratory Enterprises in China, 2015
  • Development History of In Vitro Diagnostic Industry in China
  • Market Size of In Vitro Diagnostic Industry in China, 2009-2015
  • Market Structure of In Vitro Diagnostic Reagent Industry in China, 2015
  • Comparison of Diagnostic Instrument Varieties between Domestic and Foreign Enterprises
  • Competition Pattern of Diagnostic Reagent Industry in China
  • IVD Revenue and Market Share of Major Diagnostic Reagent Enterprises in China, 2013-2015
  • Business Revenue and Inspection Revenue of Public Hospitals in China, 2014
  • Per Capita Inspection Fees and % of Outpatient Expenses of Outpatients in Chinese Hospitals, 2010-2014
  • Per Capita Inspection Fees and % of Hospitalization Expenses of Inpatients in Chinese Hospitals, 2010-2014
  • Business Revenue and Inspection Revenue of Public Hospitals in China by Type of Visit, 2014
  • Medical Services of Health Agencies in China, 2012-2015
  • Number of Medical Institutions in China, 2012-2015
  • Health Expenditure and % of GDP in China, 1980-2015
  • Per Capita Health Expenditure and YoY Growth in China, 2006-2015
  • Revenue and Net Income of KingMed Diagnostics, 2012-2015
  • Revenue Breakdown of KingMed Diagnostics by Business, 2012-2015
  • Revenue Breakdown of KingMed Diagnostics by Region, 2012-2015
  • Gross Margin of KingMed Diagnostics by Business, 2012-2015
  • R&D Costs and % of Total Revenue of KingMed Diagnostics, 2012-2015
  • Proposed Fundraising & Investment Projects and Value of KingMed Diagnostics, 2016
  • Distribution of Independent Clinical Laboratories of KingMed Diagnostics, as of June 2016
  • Capacity and Output of KingMed Diagnostics (by Business), 2014-2015
  • Service Prices of KingMed Diagnostics (by Business), 2012-2015
  • Revenue of Dian Diagnostics from Top 5 Clients and % in Total Revenue, 2012-2015
  • Revenue of KingMed Diagnostics from Top 5 Clients and % of Total Revenue, 2014-2015
  • Procurement of KingMed Diagnostics from Top 5 Suppliers and % of Total Procurement, 2014-2015
  • Revenue and Net Income of KingMed Diagnostics, 2015-2020
  • Revenue and Net Income of Dian Diagnostics, 2010-2016
  • Revenue Breakdown of Dian Diagnostics by Product, 2010-2016
  • Revenue Breakdown of Dian Diagnostics by Region, 2009-2016
  • Gross Margin of Dian Diagnostics, 2010-2016
  • Gross Margin of Dian Diagnostics by Product, 2010-2015
  • R&D Costs and % of Total Revenue of Dian Diagnostics, 2010-2016
  • Dian Diagnostics' Revenue from Independent Clinical Laboratory and YoY Growth, 2009-2016
  • Revenue of Dian Diagnostics' Top 5 Clients and % in Total Revenue, 2011-2016
  • Revenue of Dian Diagnostics from Top 5 Clients and % of Total Revenue, 2015-2016
  • Procurement of Dian Diagnostics' Top 5 Suppliers and % in Total Procurement, 2011-2016
  • Procurement of Dian Diagnostics' Top 5 Suppliers and % in Total Procurement, 2015-2016
  • Revenue and Net Income of Dian Diagnostics, 2015-2020E
  • Revenue and Net Income of Da An Gene, 2010-2016
  • Revenue Breakdown of Da An Gene by Business, 2010-2016
  • Revenue Breakdown of Da An Gene by Region, 2010-2016
  • Gross Margin of Da An Gene, 2010-2016
  • Gross Margin of Da An Gene by Business, 2010-2016
  • R&D Costs and % of Total Revenue of Da An Gene, 2011-2016
  • Main Assets and Business of Da An Gene
  • Industrial Chain Layout of Da An Gene
  • Medical Resources of Sun Yat-Sen University
  • Da An Gene's Revenue from Independent Clinical Laboratory and YoY Growth, 2010-2016
  • Revenue of Da An Gene from Top 5 Clients and % in Total Revenue, 2014-2015
  • Top 5 Suppliers of Da An Gene, 2014-2015
  • Revenue and Net Income of Da An Gene, 2015-2020E
  • Revenue and Net Income of Shanghai Labway, 2013-2016
  • Revenue Breakdown of Shanghai Labway by Product, 2013-2016
  • Gross Margin of Shanghai Labway by Product, 2013-2016
  • R&D Costs and % of Medical Diagnosis Service's revenue of Nymphavn Biotechnology, 2013-2016
  • Revenue from and Gross Margin of Independent Clinical Laboratory Business of Medicalsystem Biotechnology, 2013-2016
  • Revenue of Shanghai Labway's Top 5 Clients and % in Total Revenue, 2013-2015
  • Revenue of Shanghai Labway's Top 5 Clients and % in Total Revenue, 2015
  • Procurement of Shanghai Labway' Top 5 Suppliers and % in Total Procurement, 2013-2015
  • Procurement of Shanghai Labway' Top 5 Suppliers and % in Total Procurement, 2015
  • Revenue and Net Income of Nymphavn Biotechnology, 2009-2016
  • Revenue Breakdown of Nymphavn Biotechnology by Product, 2009-2016
  • Gross Margin of Nymphavn Biotechnology, 2009-2016
  • Gross Margin of Nymphavn Biotechnology by Product, 2009-2016
  • R&D Costs and % of Total Revenue of Nymphavn Biotechnology, 2011-2016
  • Revenue from and Gross Margin of Independent Clinical Laboratory Business of Nymphavn Biotechnology, 2009-2016
  • Revenue and Net Income of Nymphavn Biotechnology, 2015-2020E
  • Subsidiaries and Main Businesses of Surexam Biotechnology
  • Revenue and Net Income of Surexam Biotechnology, 2011-2016
  • Revenue Breakdown of Surexam Biotechnology by Business, 2011-2016
  • Gross Margin of Surexam Biotechnology, 2011-2016
  • Gross Margin of Surexam Biotechnology by Product, 2009-2016
  • R&D Costs and % of Total Revenue of Surexam Biotechnology, 2011-2016
  • Revenue from and Gross Margin of Independent Clinical Laboratory Business of Surexam Biotechnology, 2011-2016
  • Revenue of Surexam Biotechnology from Top 5 Clients and % of Total Revenue, 2015
  • Procurement of Surexam Biotechnology from Top 5 Suppliers and % of Total Procurement, 2015
  • Revenue and Net Income of Surexam Biotechnology, 2015-2020E
  • Revenue and Net Income of Medicalsystem Biotechnology, 2011-2016
  • Revenue Breakdown of Medicalsystem Biotechnology by Product, 2011-2016
  • Gross Margin of Medicalsystem Biotechnology by Product, 2011-2016
  • R&D Costs and % of Total Revenue of Medicalsystem Biotechnology, 2011-2016
  • Projects Proposed/Under Construction of Medicalsystem Biotechnology
  • Revenue from and Gross Margin of Independent Clinical Laboratory Business of Medicalsystem Biotechnology, 2011-2016
  • Revenue of Medicalsystem Biotechnology' Top 5 Clients and % in Total Revenue, 2011-2016
  • Procurement of Medicalsystem Biotechnology' Top 5 Suppliers and % in Total Procurement, 2011-2016
  • Revenue and Net Income of Medicalsystem Biotechnology, 2015-2020E
  • Revenue and Net Income of Beijing Lawke, 2013-2016
  • Revenue Breakdown of Beijing Lawke by Region, 2014-2016
  • Gross Margin of Beijing Lawke by Business, 2013-2016
  • Revenue and Net Income of Beijing Lawke, 2015-2020E
  • Revenue and Net Income of Lepu Gene, 2013-2016
  • Gross Margin of Lepu Gene,2013-2016
  • Revenue and Net Income of Lepu Gene, 2015-2020E
  • Revenue and Net Income of Biotecan,2013-2016
  • Revenue Breakdown of Shanghai Biotecan by Business 2014-2016
  • Gross Margin of Shanghai Biotecan, 2014-2016
  • Clinical Laboratory Revenue of Shanghai Biotecan and % of Total Revenue, 2013-2016
  • Revenue and Net Income of Biotecan, 2015-2020E
  • Revenue and Net Income of Jiangsu Superbio, 2014-2015
  • Revenue Breakdown of JiangsuSuperbio by Business,2014-2015
  • Revenue Breakdown of S Jiangsu Superbio by Region,2014-2015
  • Gross Margin of Jiangsu Superb by business,2014-2015
  • Revenue of Jiangsu Superb from Top 5 Clients and % of Total Revenue, 2014-2015
  • Procurement of Jiangsu Superb from Top 5 Suppliers and % of Total Procurement, 2014-2015
  • Revenue and Net Income of Jiangsu Superbio, 2015-2020
  • Milestones of Kindstar Global
  • Some Strategic Partners of ADINOVO
  • Chinese Independent Clinical Laboratory Market Size and YoY Growth, 2014-2020E
  • Revenue of Major Independent Clinical Laboratory Enterprises in China, 2011-2016
  • Clinical Laboratory Revenue of Major Enterprises in Independent Clinical Laboratory Industry in China, 2012-2016
  • Gross Margin of Major Enterprises in Independent Clinical Laboratory Industry in China, 2012-2016
  • Gross Margin of Clinical Laboratory Business of Major Independent Clinical Laboratory Enterprises in China, 2012-2016
Back to Top